Baxter International (BAX) Shares are Down -1.61%

Baxter International (BAX) : During the past 4 weeks, traders have been relatively bearish on Baxter International (BAX), hence the stock is down -1.54% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.96% relative to the S&P 500. The 4-week change in the price of the stock is -1.75% and the stock has fallen -1.61% in the past 1 week.

Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 1.95% and the fifty day Moving Average is 0.91%. Baxter International Inc. is up 9.26% in the last three month period. Year-to-Date the stock performance stands at 24.4%.

Baxter International (BAX) : The most positive equity analysts on Baxter International (BAX) expects the shares to touch $60, whereas, the least positive believes that the stock will trade at $47 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $50.57 with an expected fluctuation of $4.54 from the mean.


Baxter International (NYSE:BAX): stock turned positive on Friday. Though the stock opened at $47.24, the bulls momentum made the stock top out at $47.54 level for the day. The stock recorded a low of $46.92 and closed the trading day at $47.18, in the green by 0.17%. The total traded volume for the day was 3,197,948. The stock had closed at $47.1 in the previous days trading.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.